Lisata Therapeutics, Inc. (NASDAQ:LSTA – Get Rating)’s share price fell 3.1% during mid-day trading on Tuesday . The company traded as low as $3.22 and last traded at $3.32. 3,505 shares were traded during trading, a decline of 74% from the average session volume of 13,492 shares. The stock had previously closed at $3.43.
Lisata Therapeutics Stock Down 3.1 %
The company has a market capitalization of $26.10 million, a PE ratio of -0.27 and a beta of 1.17. The company’s 50-day moving average price is $3.41.
Institutional Investors Weigh In On Lisata Therapeutics
Large investors have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP purchased a new position in shares of Lisata Therapeutics in the third quarter worth about $57,000. State Street Corp acquired a new position in Lisata Therapeutics in the third quarter valued at approximately $66,000. BlackRock Inc. purchased a new stake in Lisata Therapeutics in the third quarter valued at approximately $263,000. Renaissance Technologies LLC acquired a new position in shares of Lisata Therapeutics in the third quarter valued at approximately $467,000. Finally, BML Capital Management LLC purchased a new stake in shares of Lisata Therapeutics in the fourth quarter valued at approximately $617,000. 6.00% of the stock is owned by hedge funds and other institutional investors.
Lisata Therapeutics Company Profile
Lisata Therapeutics, Inc develops biopharmaceuticals. It is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. It is designed to modify the tumor microenvironment by activating a novel uptake pathway that allows anti-cancer drugs to penetrate solid tumors more effectively.
- Get a free copy of the StockNews.com research report on Lisata Therapeutics (LSTA)
- Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
- GitLab Crashes On Guidance; Analysts Defend
- Healthcare Stocks With at Least 30 Years of Dividend Increases
- Coinbase Pops As SVB Crumbles To Dust
- Airlines Update Guidance, Shares Head For Different Destinations
Receive News & Ratings for Lisata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lisata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.